AC Immune says Parkinson's drug slows progression AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

Swiss biotech #ACImmune has said that its vaccine-like alpha-synuclein-targeted #immunotherapy has shown promise in slowing down the progression of #Parkinsonsdisease.

AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial - PharmaTimes Early-stage study reveals strong immune response and safety profile for ACI-35.030

#ACImmune #AlzheimersDisease #Tautargetingtherapy #Alzheimerstrial #ACI35030 #Tautargetingactiveimmunotherapy #immunotherapy #earlyAlzheimersdisease #SupraAntigentechnology #JACI35054 #polyclonalantibody #Tau #phosphorylatedTau #pTau #brainderivedTau #ePHF #ReTaintrial
zurl.co/MY6hl

(NASDAQ: #ACIU)
#ACImmune trims 30% of its workforce and sharpens its pipeline focus, extending its cash runway through Q3 2027. A strategic reset aiming for efficiency and long-term sustainability.
prismmarketview.com/ac-immune-re...

Und gleich hinterher eine Aktienplatzierung zu 3,50 Dollar mit etwa 50 Millionen Dollar Volumen. Killt leider etwas das gerade entstandene Momentum beim Aktienkurs. Mal gespannt was im "regulären" Nasdaq-Handel passiert... ir.acimmune.com/news-release... #acimmune $ACIU

Interessanter Meilenstein für #ACImmune $ACIU bei #Alzheimer mit vielen Millionen von #Janssen ... ir.acimmune.com/news-release...